N urses play a signifi cant role in the care of adult patients with idiopathic thrombocytopenic purpura (ITP) and chronic lymphocytic leukemia (CLL). Patient and caregiver education about the diseases and their treatment options and side effects is critical. Oncology nurses should have a thorough understanding of standard therapeutic strategies and newer targeted therapies to educate patients and caregivers. Maintaining understanding is a significant and ongoing challenge for oncology nurses because of the large number of standard treatment options, investigational agents, and regimens under study in clinical trails.
Idiopathic Thrombocytopenic Purpura

Defi nition and Etiology
ITP is an autoimmune disorder characterized by autoantibody binding to platelet antigens. The binding induces premature destruction of platelets, particularly by the spleen but also by other components of the reticuloendothelial system, which is composed primarily of blood monocytes and tissue macrophages, resulting in thrombocytopenia (British Society for Haematology, 2003; Crow, Song, Siragam, & Lazarus, 2006; George et al., 1996) .
ITP is defi ned as isolated thrombocytopenia without other signifi cant abnormalities on complete blood count or peripheral blood smear. It can be a primary or secondary disorder. The etiology of primary ITP is unknown; however, secondary ITP is associated with certain medications, infections, other autoimmune diseases, transfusions, or pregnancy. The most common diagnosis of secondary ITP in malignant disease is in patients with CLL (British Society for Haematology, 2003; George et al., 1996) . This article will focus on adult primary ITP.
